Immunic (NASDAQ:IMUX) Raised to Hold at StockNews.com

Immunic (NASDAQ:IMUX) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other research analysts have also weighed in on IMUX. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a research report on Tuesday, January 7th. HC Wainwright initiated coverage on Immunic in a research note on Monday, November 25th. They set a “buy” rating and a $10.00 target price on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Immunic has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Price Performance

Shares of IMUX opened at $0.98 on Friday. Immunic has a one year low of $0.92 and a one year high of $2.11. The company has a 50-day moving average of $1.09 and a two-hundred day moving average of $1.30. The stock has a market cap of $88.28 million, a price-to-earnings ratio of -0.80 and a beta of 1.88.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). During the same period in the previous year, the firm posted ($0.51) EPS. Analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

Insider Transactions at Immunic

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, with a total value of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares of the company’s stock, valued at approximately $100,395. The trade was a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. increased its position in Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. State Street Corp boosted its stake in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Immunic in the 3rd quarter valued at approximately $50,000. Finally, HB Wealth Management LLC acquired a new stake in Immunic in the 4th quarter worth approximately $81,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.